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ABSTRACT 
Background: Severe mental illness, including schizophrenia is associated with an increased 
risk of premature death by somatic conditions and in particular by cardiovascular events. 
Reducing cardiovascular risk factors in patients with psychotic disorder is urgently called for.  
Aim: This thesis describes frequencies of cardiovascular risk factors among patients with 
psychosis. Clinical and genetic factors affecting plasma concentration of clozapine and their 
respective relation to increased fasting glucose and waist circumference are evaluated. In the 
last part of the thesis, levels of three biomarkers associated with cardiovascular risk are 
determined among patients with psychosis. 
Methods: In two papers (Studies I and III), patients with psychosis recruited from outpatient 
clinics in Stockholm County Sweden were compared to non-psychotic control subjects from 
the population. Clinical and genetic factors related to plasma concentration of clozapine were 
explored in a sample of 113 patients on clozapine treatment (Study II). In one study (Study 
III), pharmacological treatment of diabetes was compared between 977 patients with 
psychosis and 3908 control subjects. In patients with psychosis and diabetes, factors 
associated with pharmacological treatment of diabetes were determined. In the last 
manuscript (study IV), levels of the biomarkers hsTnT, hsCRP and NT-BNP were 
determined in 300 patients with psychotic disorder.  
Results: Psychosis was associated with higher fasting glucose levels, increased waist 
circumference and higher frequency of smoking compared to controls. Furthermore, 50 
percent of patients with psychosis fulfilled the criteria for metabolic syndrome. Both 
prediabetes and diabetes were approximately three times more frequent among patients with 
psychosis as compared to controls. Of patients with psychosis and prediabetes 77 percent also 
fulfilled the criteria for metabolic syndrome. Genetic variants of CYP1A2 and MDR1, and 
smoking were associated to lower plasma concentrations of clozapine. Levels of biomarkers, 
in previous studies associated with elevated cardiovascular risk, were elevated above 
reference values in patients with psychosis. 
Conclusion: Reduced conversion from prediabetes to manifest diabetes is proposed as a 
treatment goal for patients with psychosis. Regular therapeutic drug monitoring is advised 
when clozapine is used. Longitudinal evaluation of biomarkers of cardiovascular risk would 
add valuable information to the clinician caring for patients with psychosis. 
Keywords: Cardiovascular risk, psychosis, metabolic syndrome, diabetes, prediabetes, waist 
circumference, smoking, healthy individuals, clozapine, plasma concentration, genetics, 
single nucleotide polymorphisms (SNPs), CYP1A2, MDR1, high-sensitive troponin T 
(hsTnT), high-sensitive C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic 
peptide (NT-BNP) 
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1 INTRODUCTION 
1.1 TIMELINE 
My work in the psychiatric field started in 2007 when I became a resident physician at the 
psychiatric clinic at Danderyd University Hospital. Urban Ösby who later became my main 
supervisor was working at the clinic and introduced me to psychiatric research. Early on I 
found patients with psychotic symptoms to be engaging. It is difficult for me to understand 
how someone is not intrigued by these diseases. The core symptoms of psychosis, 
hallucinations and delusions ruthlessly show how important the mind is. Urban Ösby with his 
burning enthusiasm for this patient group inspired me enormously to start my research. 
During the first three years we were working on a project focusing on genetic risk factors for 
suicide among patients with schizophrenia. 480 patients with schizophrenia who had died 
from suicide were identified through the Patient Register and the Cause of Death Register of 
the Swedish National Board of Health and Welfare. The time period was 1974-2006 and four 
major forensic regions in Sweden: Stockholm, Uppsala, Linköping and Lund were included. 
We started collecting biological material from the autopsies of the cases. We also identified 
patients with schizophrenia from the same time period who had died by unnatural causes but 
where the cause of death had not been classified as suicide. Since there are no national 
guidelines or decision-trees in forensic medicine to standardize the diagnostic procedure for 
determining if the cause of death is suicide or not, we formulated an algorithm and evaluated 
the pathology records of each case. The forensic or pathology records encompass somatic and 
psychiatric medical information, police reports, autopsy protocols, as well as results from 
chemical, toxicological and microscopic examinations. We slowly also started experiencing 
problems with the extraction of deoxyribonucleic acid (DNA) from the paraffin embedded 
tissue samples. Filled with enthusiasm we had not anticipated this. Central to the problem is 
that DNA gets fragmented during the purification process. To small fragments means that 
genes, which are large fragments of DNA, are very difficult to amplify and analyze. Although 
this project now finally seems to pay off, analyzing RNA and gene expression in contrast to 
DNA, we back then had to change course for my PhD project. It is well known also to the 
public that patients with severe mental illness have higher mortality in suicide compared to 
the general population. Less appreciated, also among physicians and psychiatrists, is the fact 
that the overall difference in mortality comparing patients with psychosis and the general 
population is to a large extent caused by cardiovascular disease, other somatic conditions and 
suicide. Patients with psychosis die from ordinary causes but at younger age compared to the 
population. Why do these patients have a higher risk for these conditions? An important way 
to improve the prognosis of schizophrenia would be to study why these patients have 
increased risk of cardiovascular disease, and to use the answer as guidance for counteraction. 
I decided to have this as my PhD research field. As this thesis goes to print, the United 
Nations have recently adopted developmental goals. These goals include commitment to 
reduce by one third premature mortality from non-communicable diseases for all at all ages 
by 2030.  
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1.2 SCHIZOPHRENIA AND RELATED DISORDERS 
Severe mental illness is often characterized by a diagnosis of non-organic psychosis, 
prolonged illness and disability (Schinnar, Rothbard, Kanter, & Jung, 1990). Schizophrenia, 
one of the most common severe mental illnesses, has an estimated point prevalence of about 
four per 1000 (Saha, Chant, Welham, & McGrath, 2005). The condition is considered to be a 
major contributor of the global burden of disease (Whiteford et al., 2013). In Sweden the 
psychiatric outpatient clinics are divided in two different types, psychosis outpatient clinics 
and general psychiatric outpatient departments. Somatic health problems are treated in 
separate general practice outpatient clinics. This division and sub-specialization, generally 
occurring in the health care system, might be problematic for patients with schizophrenia, 
possibly creating a barrier to somatic health care. As of today, there seems to be no evidence 
that distance between disciplines will decrease over time. 
Schizophrenia, as well as other severe mental illnesses, are well known to be associated with 
elevated suicide rates, with five percent dying of suicide (Palmer, Pankratz, & Bostwick, 
2005). Less widely appreciated is the fact that schizophrenia is associated with a clearly 
increased risk of premature death by many other somatic conditions (Brown, 1997). As a 
result, the risk of cardiovascular mortality in schizophrenia is doubled compared to the 
general population (Laursen et al., 2013; Osby, Correia, Brandt, Ekbom, & Sparen, 2000). 
Moreover, standardized mortality rates (SMRs) for schizophrenia seem to be worsening over 
time (Saha, Chant, & McGrath, 2007). 
A spectrum approach to mental diseases means that linked conditions or symptoms are 
grouped together. Schizophrenia with this approach forms psychosis spectrum disorders or 
schizophrenia spectrum disorders. In this thesis, where psychosis patients from outpatient 
clinics were studied, we included all patients in regular treatment. Previous findings strongly 
suggest that biological mechanisms of mental disorders are more likely to be found with a 
spectrum approach as opposed to a strict categorical approach. 
Physical health monitoring typically occurring in primary care settings, has been suggested to 
be performed by mental health care providers to detect and intervene risk factors for somatic 
illness (Marder et al., 2004). These recommendations include monitoring of body mass index 
(BMI), plasma glucose level, lipid profiles, side effects of medication and specific 
recommendations for cardiac monitoring (Marder et al., 2004). A similar approach with 
regular monitoring has been included in Swedish clinical guidelines concerning 
schizophrenia and other psychotic disorders since 2009 (Gothefors et al., 2010). 
1.3 CARDIOVASCULAR RISK FACTORS 
There are several risk factors for cardiovascular disease. Diabetes mellitus, elevated lipid 
levels, and hypertension, increased waist circumference and smoking are the most important. 
Severe mental illness has previously been shown to be associated with increased prevalence 
of metabolic changes (Goff et al., 2005; Mackin, Bishop, Watkinson, Gallagher, & Ferrier, 
2007). The mechanisms behind these changes are probably complex and could be explained 
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by shared genetics, adverse effects of antipsychotic treatment or lifestyle factors (Saha et al., 
2007). 
1.3.1 Metabolic syndrome 
The metabolic syndrome is a set of important cardiovascular risk factors. In the studies for 
the present thesis we have used the operational criteria for metabolic syndrome defined by the 
International Diabetes Federation (IDF). In this definition increased waist circumference 
(ethnicity-specific values: ≥ 94 cm in male and ≥ 80 cm in female European Whites) is a 
main criteria that has to be fulfilled for the condition to be present. Any two of the following 
four factors: elevated triglycerides (≥ 1.7 mmol/L), reduced HDL cholesterol (< 1.03 mmol/L 
in males and < 1.29 mmol/L in females), elevated blood pressure (systolic ≥ 130 mm Hg, 
diastolic ≥ 85 mm Hg, or antihypertensive treatment), and elevated fasting plasma glucose (≥ 
5.6 mmol/L or antidiabetic drug treatment) must also be present (Alberti, Zimmet, & Shaw, 
2006). 
1.3.2 Smoking 
Smoking is a risk factor associated with adverse health outcomes e.g. myocardial infarction, 
cerebrovascular incidents, hypertension and neoplasms. The prevalence of smoking in 
patients with schizophrenia varies between 40 and 60 percent in different studies with 
different samples (Mackin et al., 2007; Osborn, Nazareth, & King, 2006). Generally, hospital 
based samples have higher prevalence of smoking. The prevalence of smoking in the current 
material was 41 percent. 
Smoking is often regarded as a self-medication to improve cognitive deficits, either 
attributable to the illness or side effects of antipsychotic medication. Several studies have 
shown that measures of attention are improved by smoking (Ahlers et al., 2014; Segarra et al., 
2011). Interestingly a recent study has also suggested an association between smoking and 
increased risk of developing psychosis (Gurillo, Jauhar, Murray, & MacCabe, 2015). Despite 
the notoriously high prevalence of smoking among patients with psychotic disorders and the 
established association between smoking and adverse health outcomes, smoking cessation 
studies are scarce. 
1.3.3 Diabetes and glucose disturbances 
In the following studies of the thesis, the diagnostic criteria of the WHO and IDF were used 
to define diabetes and prediabetes. According to these criteria, diabetes mellitus (DM) is 
defined as fasting glucose ≥7.0 mmol/L and prediabetes as fasting glucose, 6.1–6.9 mmol/L 
(Alberti & Zimmet, 1998). The progression rates from prediabetes to type 2 diabetes differ by 
definition of prediabetes. Previous epidemiological studies suggest that approximately 25% 
of patients with prediabetes progress to type 2 diabetes in 5 years, 50% remain with 
prediabetes and 25% revert to normal (Larsson, Lindgarde, Berglund, & Ahren, 2000). 
Higher progression rates, especially among more obese subjects, averaging 10-12% per year, 
have been suggested in other studies (Knowler et al., 2002; Tuomilehto et al., 2001). Lifestyle 
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interventions and oral antidiabetic agents have been reported to reduce the progression from 
prediabetes to manifest type 2 diabetes. The drug metformin has been demonstrated to reduce 
incident type 2 diabetes by 31% compared to control subjects who received placebo 
(Knowler et al., 2002). Other pharmacological agents than metformin have also been studied 
but metformin remains the first hand choice due to its safety data, efficacy, and cost profile. 
Life style interventions have often been shown to be more effective than pharmacological 
treatment in reducing the progression. However, the positive effects of life style interventions 
appear to be difficult to maintain over the long term. Partly due to the risk of side effects, 
pharmacological interventions have been suggested primarily for patients with prediabetes at 
particular risk for developing diabetes. 
1.3.4 Overweight, BMI and waist circumference 
Obesity is the most potent acquired risk factor for developing type 2 diabetes. The age-
adjusted relative risk of developing type 2 diabetes is ~10-fold higher for men with a BMI of 
30 kg/m2 relative to men with a BMI < 23 kg/m2 and the risk is even higher for women, 
where a BMI of 30 kg/m2 is associated with a ~30-fold higher risk (Chan, Rimm, Colditz, 
Stampfer, & Willett, 1994; Colditz, Willett, Rotnitzky, & Manson, 1995). 
Especially intra-abdominal obesity is associated with cardiovascular disease (CVD), 
dyslipidemia, type 2 diabetes and insulin resistance (Despres, Lemieux, & Prud'homme, 
2001; Eckel, Alberti, Grundy, & Zimmet, 2010; Emery, Schmid, Kahn, & Filozof, 1993). 
There are essentially two ways of measuring intra-abdominal obesity: waist circumference 
and waist-to-hip ratio. The two measurements both seem to be equal in predicting CVD risk 
(de Koning, Merchant, Pogue, & Anand, 2007). Since waist-to-hip ratio involves two 
measurements and waist circumference only one, the latter may be preferred by the clinician. 
1.4 ANTIPSYCHOTIC DRUGS 
Antipsychotic drugs have high affinity for the dopamine receptor D2 (DRD2) and the 
antipsychotic effect is thought to be a result of blocking of this receptor. Antipsychotic drugs 
are commonly divided into two groups, first-generation antipsychotics (FGAs) and second-
generation antipsychotics (SGAs). This division is based on when the drugs were developed, 
with exception of clozapine, an SGA developed during the 1950s. 
SGAs are associated with fewer extrapyramidal symptoms and have a similar efficacy 
compared to FGAs. SGAs also have a reduced risk of discontinuation and relapse compared 
to FGAs. However, SGAs and especially olanzapine and clozapine are associated with an 
increased risk of weight gain and metabolic abnormalities (Hert, Detraux, van Winkel, Yu, & 
Correll, 2012). Lack of the drug to alleviate symptoms associated with psychosis and side 
effects, such as weight gain, extrapyramidal symptoms or sedation are often primary reasons 
for discontinuation.  
Antipsychotic drugs also to a varying degree seem to have direct cardiac effects. Both FGAs 
and SGAs have been reported to be associated to prolonged corrected QT interval (QTc) 
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(Elbe & Savage, 2010; Strom et al., 2011). Furthermore, antipsychotic drugs have also been 
associated with myocarditis and cardiomyopathy. This association seems to be most 
pronounced for clozapine (Coulter, Bate, Meyboom, Lindquist, & Edwards, 2001). Due to 
the potential side effects of antipsychotic drugs and the markedly increased risk of 
cardiovascular morbidity and mortality among psychosis patients, close monitoring of 
cardiovascular risk factors have been recommended. Regular assessment of fasting glucose, 
blood pressure, waist circumference and lipids have been suggested as important measures 
(Hert et al., 2012; Khasawneh & Shankar, 2014). Electrocardiography before initiation of 
antipsychotic treatment (Hert et al., 2012) and in the case of clozapine treatment, a low 
threshold to perform echocardiography have also been advocated (Alawami, Wasywich, 
Cicovic, & Kenedi, 2014). 
1.4.1 Clozapine 
Clozapine is an SGA with structural resemblance to olanzapine. It was  first synthesized in 
1958 (Crilly, 2007). Since its introduction, withdrawal and re-introduction on the market, 
clozapine stands out compared to other antipsychotic drugs with regard to both efficacy and 
side effects. It is considered especially effective in treatment-resistant schizophrenia (J. Kane, 
Honigfeld, Singer, & Meltzer, 1988; J. M. Kane, 1996). Furthermore, clozapine is the only 
antipsychotic drug with a significant association to reduced suicidality (Hennen & 
Baldessarini, 2005). Considering side effects, clozapine seems to have a high propensity to 
produce weight gain and metabolic disturbances. Agranulocytosis as a potential side effect is 
well recognized and regular monitoring of white blood cells is mandatory in many countries 
including Sweden. Recently, a less rigorous long time white blood cell monitoring has been 
proposed in Sweden (Olsson, Lennestal, & Hagg, 2015). Maybe less appreciated is 
clozapine’s ability to cause electroencephalographic changes and seizures (Leucht et al., 
2013). 
An overview of clozapine treatment in Sweden during 2012 is presented in Table 1. During 
2012 approximately 18 percent of patients with a diagnosis of schizophrenia or 
schizoaffective disorder with antipsychotic treatment were treated with clozapine. Since the 
Drug Prescription Register of the Swedish National Board of Health and Welfare was not in 
full use until the end of 2006, a washout period from 2007-2011 was used for incident cases 
of clozapine during 2012. The time period 2007-2012 was used to calculate duration of 
treatment for all patients with clozapine and for patients discontinuing treatment. The time to 
discontinuation of treatment has previously in several naturalistic studies been shown to be 
longer for atypical than typical antipsychotics. Furthermore, within the group of atypical 
antipsychotics clozapine and olanzapine seem to contribute most to longer duration to 
treatment discontinuation (Ascher-Svanum et al., 2006). 
 
 12 
Table 1. Antipsychotic treatment and duration of clozapine treatment in Sweden during 2012 
according to data from the Swedish Drug Prescription Register, National Board of Health and 
Welfare* 
Schizophrenia or schizoaffective 
disorder 
18 114 Duration of treatment (years) 
 Antipsychotic treatment 16 964   ND 
 Clozapine treatment 3 003 (18) 4.8 (5.8) 
 Discontinued clozapine treatment 180 (6) 2.9 (2.9) 
 Started clozapine treatment 551 (18) NA 
*Data reported as number, number (%) or mean (median) 
NA, not applicable; ND, not determined 
 
1.4.2 Drug-metabolizing enzymes and transport proteins 
Many different enzymes are involved in drug metabolism, including the hepatic cytochrome 
(CYP) P450s which are important for the metabolism of many drugs including antipsychotics 
(Sheweita, 2000). Concerning clozapine, the isoenzyme CYP1A2 is thought to be primarily 
responsible for the metabolism (Bersani et al., 2011). Other enzymes such as uridine 
diphosphate glucuronosyltransferase 1A4 (UGT1A4) have also been suggested to affect inter 
individual variability (Erickson-Ridout, Sun, & Lazarus, 2012). Multidrug resistance protein 
1 (MDR1), a transport protein expressed in the liver, kidneys and the blood-brain barrier may 
also affect plasma concentration and consequently the pharmacological effect of the 
compound (Bersani et al., 2011; Consoli et al., 2009). 
1.4.3 Investigated genes regulating metabolism of clozapine  
The genes investigated in this thesis encode the enzymes and the transport protein involved or 
suggested to be involved in the metabolism of clozapine. A functional variant of a gene 
affecting metabolism should be reflected in a different concentration of the drug metabolized 
by the enzyme. The specific variants of the genes and their respective suggested effect on 
function of the protein are shown in Table 2. 
The CYP1A2 gene is located on chromosome 15q24.1 and encodes a protein which catalyzes 
many reactions involved in drug metabolism. The enzyme mediates the rate-limiting step in 
the metabolism of different drugs including clozapine, olanzapine and caffeine (Faber, Jetter, 
& Fuhr, 2005). CYP1A2 is expressed mainly in the liver and is induced by polycyclic 
aromatic hydrocarbons (PAHs) found in cigarette smoke (Bersani et al., 2011). 
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The MDR1 gene is located on chromosome 7q21.1 and encodes a P-glycoprotein which 
functions as efflux pump from the inside of the cell to the outside (Brinkmann, 2002).  
The UGT1A4 gene is located on chromosome 2q37 and encodes an enzyme regulating the 
transformation of drugs into water soluble metabolites. In the case of clozapine, UGT1A4 has 
been suggested to affect inter individual variability of plasma concentration (Erickson-Ridout 
et al., 2012). 
 
 
Table 2. Genetic variants studied and corresponding functional effect 
Gene and Single Nucleotide 
Polymorphism 
Functional 
effect  
CYP1A2   
 CYP1A2*1D -2467delT Unknown 
 rs35694136  
 CYP1A2*K -729C>T Activity ↓ 
 rs12720461  
 CYP1A2*F -163C>A Activity ↑ 
 rs762551  
MDR1  
 -3435C>T (Expression ↓) 
 rs1045642  
 -2677G>T Unknown 
 rs2032582  
UGT1A4  
 L48V -142T>G Activity ↓ 
 rs2011425  
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2 AIMS 
The main objectives of this thesis were (1) to assess cardiovascular risk factors and 
pharmacological treatment of diabetes, and (2) to assess the clinical relevance of genetic 
variants on clozapine plasma concentration in patients with psychotic disorder.  
The specific aims related to each paper were: 
• To assess differences in waist circumference, fasting glucose and tobacco use in 
patients with psychotic disorder compared to population controls from the same 
geographical area (Study I). 
 
• To assess the effect of age, gender, smoking status, weight and genetic variants of 
CYP1A2, MDR1 and UGT1A4  on plasma levels of clozapine (Study II). 
 
• To study relation between plasma concentrations of clozapine and waist 
circumference and fasting glucose levels (Study II). 
 
• To assess prevalence of diabetes, prediabetes and antidiabetic treatment in patients 
with psychotic disorder compared to population controls (Study III). 
 
• To study what factors are associated to pharmacological antidiabetic treatment when 
diagnosed with diabetes and a psychotic disorder (Study III). 
 
• To determine levels of three biomarkers associated with cardiovascular risk in 300 
psychosis patients (Study IV). 
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3 METHODS 
3.1 STUDY POPULATION SWEDISH STUDY OF METABOLIC RISKS IN 
PSYCHOSIS (SMRP) 
The study sample of this thesis emanates from a sample of psychosis patients recruited during 
the years 2005-2010 in the Swedish Study of Metabolic Risks in Psychosis (SMRP). In 
Sweden, special psychiatric outpatient clinics have treatment responsibility for all patients 
with chronic psychotic disorders. The patients were recruited consecutively from psychosis 
outpatient clinics mainly in Stockholm County, Sweden as a part of an assessment of general 
health. Of the total number of patients, 75 percent were recruited in Stockholm County. 
Psychiatric diagnoses were confirmed by the clinicians according to the DSM-IV (American 
Psychiatric Association., 2000). Data was collected with a psychiatric questionnaire 
containing information on diagnosis, global assessment of functioning (GAF) (Aas, 2011) 
and clinical global impression (CGI) (Busner & Targum, 2007), duration of illness, duration 
of treatment, duration of hospitalization during the last year. All present medication, 
including dosages, were confirmed in case notes and recorded.  
Patients with psychosis were assessed with a questionnaire about somatic health. This 
questionnaire included perceived degree of health, questions about diabetes, hypertension, 
current tobacco use, and previous diagnosis of myocardial infarction. It also included 
questions covering alcohol use, chest pain during the last year, dyspnea and diabetes among 
first-degree relatives. Waist circumference, blood pressure, length and body weight were 
measured. Cases were given written instruction to be fasting overnight before venous blood 
sampling. 
3.2 CONTROL SUBJECTS STUDY I AND III 
The control subjects in study I and III were participants in a follow-up study of a population 
based survey, the Stockholm Diabetes Prevention Program (SDPP). The follow-up study was 
performed during 2002-2006, eight to ten years after baseline. The sample in the follow-up is 
described in detail in previous studies (Eriksson et al., 2008). Since one of the main aims of 
the follow-up study was to investigate the effect of family history of diabetes on the risk of 
glucose disturbances, the whole sample was selected from all responders and enriched for 
family history of diabetes. The enrichment was made so that half had a family history of 
diabetes. Concerning diabetes, patients who already had a diagnosis or were diagnosed during 
the health examination at baseline, were excluded from the follow-up. Hence, diabetes cases 
among controls in the present thesis, are only subjects who developed diabetes between 
baseline and follow-up. 
All present medication and dosages were recorded. Controls were asked about family history 
of diabetes, defined as at least one first-degree relative with known diabetes. Somatic health 
was assessed with a questionnaire, covering diabetes, hypertension, and tobacco use. Body 
weight, height, waist circumference and blood pressure were measured.  
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Fasting plasma glucose (FPG) was measured in all controls. In addition, controls without a 
diagnosed diabetes went through an oral glucose tolerance test. 
3.3 METHOD FOR EACH PAPER 
3.3.1 Study I 
In the first study of the thesis 731 patients with psychotic disorder, recruited consecutively 
from outpatient clinics in Stockholm were compared to 5580 population controls with respect 
to cardiovascular risk factors. The cardiovascular risk factors of main interest were waist 
circumference, body mass index and fasting glucose.  
3.3.1.1 Methodological considerations 
The study design enabled us to compare frequencies of cardiovascular risk factors between a 
large outpatient sample and a population based sample of controls. Hence, the results could 
be generalizable to the population of psychosis patients. There were significant differences 
between cases and controls in age, with controls being older and in family history of diabetes 
(FHD), with higher frequency of FHD among controls. In the statistical comparisons these 
factors were controlled for, however their presence warrants some caution when interpreting 
results. The exclusion of diabetes cases among controls at baseline could bias the results, 
since diabetes cases among controls in this study were only those who developed diabetes 
between baseline and follow up. In other words patients had a longer period of time, during 
which they could develop diabetes. Antipsychotic treatment has been suggested as an 
important cause of metabolic disturbances. Unfortunately, since a vast majority of patients 
were on current treatment and no patient was likely drug naïve it was not possible to analyze 
the independent effect of antipsychotic medication. We had no socioeconomic data, data on 
dietary habits or exercise and therefore the effects of these variables were not possible to 
analyze.  
3.3.2 Study II 
Of the 731 patients in the first study, 113 (15%) were prescribed clozapine, including 74 
patients having clozapine as monotherapy. Blood samples for genetic analyses were available 
in 95 of the 113 patients and in 98 patients plasma concentrations of clozapine and the major 
metabolite norclozapine were measured. Patients were given written instructions to be fasting 
overnight and not to take their morning dose of clozapine, if prescribed twice daily, before 
venous blood sampling. Information on daily dose clozapine, concomitant medication, main 
psychiatric diagnose, fasting glucose, waist circumference, body weight, sex and smoking 
habits were recorded. Concurrent drugs possibly affecting CYP1A2 activity were identified.  
3.3.2.1 Methodological considerations 
The major strength with the study is that it is a clinical sample of patients who are being 
treated with clozapine. However this strength of the study also implies weaknesses. Most 
patients were on monotherapy with clozapine but 32 percent were taking a combination of 
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clozapine and some other antipsychotic drug. This could bias the results. Furthermore, one 
important weakness was that we had no estimate of the effect of clozapine. It is plausible that 
patients on very low doses of clozapine did not have clozapine as main antipsychotic 
pharmacotherapy and that low concentrations are effective in improving symptoms such as 
insomnia. Concerning compliance to the prescribed treatment, we had no other measurement 
than the plasma concentration. It is however noteworthy that all patients had concentrations 
above detection level. Blood samples for measurement of plasma concentration were all 
taken in the morning. Unfortunately the exact time for sampling was not standardized. To 
compensate for this a time factor was introduced based on the average half-life of clozapine. 
This average half-life however, is also an approximation. 
3.3.2.2 Genotyping 
Three different techniques were used to genotype the single nucleotide polymorphisms 
(SNPs) of interest. The different techniques used were the TaqMan method, pyrosequencing 
and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). 
Reaction conditions, sequences of interest, primers and rs numbers and the restriction enzyme 
are described in detail in the supplementary material to study II. 
3.3.3 Study III 
In this study 977 patients with psychotic disorder recruited in SMRP were compared to 3908 
population controls. The controls were randomly selected, matched on frequency of FHD 
among patients with psychosis (24%). We assessed differences between the groups in fasting 
plasma glucose levels, frequencies of diabetes, prediabetes, pharmacological antidiabetic 
treatment, and smoking habits. Differences in waist circumference, blood pressure and body 
mass index were also evaluated. In patients with a psychotic disorder and a diabetes 
diagnosis, factors associated with antidiabetic pharmacological treatment were studied. 
3.3.3.1 Methodological considerations  
As mentioned for controls in study I, the present controls included only incident diabetes 
cases diagnosed between baseline and follow-up. In this regard, cases and controls were not 
comparable in respect to occurrence of diabetes. The control subjects were nine years older 
than the patients. Since age could affect the frequency of diabetes, the comparisons were 
statistically controlled for differences in age. Controls did not go through a psychiatric 
assessment and therefore patients with psychosis might be present among controls biasing 
results. However, in retrospect the medication of controls was evaluated to detect 
antipsychotic drugs. In this evaluation, four controls had recorded use of antipsychotic drugs. 
For patients with psychosis, we had data on frequencies of the metabolic syndrome, and 
controls without a diagnosed diabetes went through an oral glucose test but not vice versa. 
Thus, comparison of the metabolic syndrome between cases and controls was not possible 
and the diagnosing of diabetes was more thorough among controls. It is well known that there 
is a considerable intrapersonal variance of fasting glucose over time. Hence it would have 
been better to use glycated hemoglobin, much more stable over time, as an assessment of 
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antidiabetic pharmacological treatment. Also, the use of one fasting glucose value when 
diagnosing diabetes could bias the results if compliance to fasting instructions before blood 
sampling differs between patients with psychosis and controls.  
3.3.4 Study IV 
Levels of three biomarkers, in previous work associated with increased cardiovascular risk, 
were studied in 300 patients with psychotic disorder, recruited in SMRP. The three 
biomarkers of interest were: N-Terminal Pro-B-Type Natriuretic Peptide (NT-BNP), high-
sensitive troponin T (hsTnT) and high-sensitive C-reactive protein (hsCRP). Data on serum 
lipid profiles, plasma creatinine and fasting plasma glucose were also available. Somatic 
health assessment was performed with a questionnaire about diabetes, hypertension, and 
previous diagnosis of myocardial infarction and current use of tobacco. Waist circumference, 
blood pressure, length and body weight were measured. In this cross-sectional study, our aim 
was to evaluate levels of biomarkers and assess potential associations between biomarkers 
and traditional clinical cardiovascular risk factors. 
3.3.4.1 Methodological considerations 
To study potential advantage of biomarkers of increased cardiovascular risk over traditional 
clinical risk factors and scoring systems, one would have to perform a longitudinal study 
containing cardiovascular events. This is of course a very interesting question for the 
clinician. Unfortunately, the current study design did not enable us to study this question. 
Hence, the study-design could be considered as a major weakness. On the other hand, one 
could argue that it is wise to test if patients with psychosis have pathological levels of 
biomarkers before starting a longitudinal study. 
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3.4 STATISTICAL ANALYSIS 
3.4.1 Study I 
Standard descriptive statistics were used to summarize all variables. Multivariate analysis of 
variance and covariance (MANCOVA) was used to study differences between patients and 
controls in continuous variables. In this analysis age and gender were entered as covariates 
because of the significant difference between cases and control subjects in these variables. 
Differences in categorical variables between cases and controls were evaluated with the χ2 
test. Associations between increased fasting glucose and increased waist circumference as 
dependent variables, and gender, group (control subject/patient with psychosis) and current 
tobacco use were tested with logistic regression. 
3.4.2 Study II 
Standard descriptive statistics were used to summarize all variables. Plasma concentration of 
clozapine corrected for daily dose, ratio of concentration to dose, was positively skewed. 
Ratios of plasma concentration to dose clozapine were therefore analyzed with the Mann-
Whitney test for differences between patients with different sex, age (<44 y, ≥44 y), smoking 
status, body weight (<90 kg, ≥90 kg) and genetic variants. The genetic variants were coded as 
dichotomous variables under a dominant or recessive model. The combined effect of 
genotype and clinical variables on plasma concentration to dose ratio clozapine was analyzed 
with linear regression. Logistic regression models were used to study potential associations 
between genetic variants, clinical variables and plasma concentration of clozapine with 
increased waist circumference and increased fasting glucose as dependents variable in each 
model respectively. 
3.4.3 Study III 
Standard descriptive statistics were used to summarize all variables. Analysis of variance and 
covariance (ANCOVA) with age and sex as covariates was used to test differences in 
continuous variables between patients with psychosis and controls for significance. 
Differences in categorical variables such as tobacco use and sex between patients and 
controls were analyzed with the χ2 test. The categorical variables antidiabetic 
pharmacological treatment (no/yes) and achievement of FPG <7 mmol/L (no/yes) were 
analyzed in logistic regression models with age, sex and group (patients with psychosis or 
controls) as independent variables. Among patients with psychosis and diabetes, associations 
between antidiabetic pharmacological treatment and clinical variables were evaluated. In this 
evaluation logistic regression was used to study the relation between antidiabetic 
pharmacological treatment as dependent variable and smoking status (ref = non-smoker), 
fasting plasma glucose (continuous), the metabolic syndrome (ref = no), waist circumference 
(continuous), Global Assessment of Functioning scale (continuous), Clinical Global 
Impression scale (continuous), antihypertensive treatment (ref = no), lipid-lowering treatment 
(ref = no), duration of antipsychotic medication (months, continuous variable), and number of 
months in hospital during the previous year (continuous variable) as independent variables. 
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We also performed two separate regression analyses with waist circumference and fasting 
glucose as dependent variables with clinical variables including duration of antipsychotic 
treatment (continuous), age (continuous), main psychiatric diagnosis (categorical) and sex 
(ref = man) as independent variables. 
3.4.4 Study IV 
Standard descriptive statistics were used to summarize all variables. The distributions of the 
biomarkers were positively skewed and were summarized with mean, median and standard 
deviation. To study univariate relations, non-parametric correlation coefficients (Kendall’s 
tau-b) were calculated between biomarkers and the clinical variables. Differences in levels of 
biomarkers and categorical variables with two categories were evaluated with the Mann-
Whitney test. Differences in levels of biomarkers and categorical variables with more than 
two categories were evaluated with the Kruskal-Wallis test. To study relations between 
clinical cardiovascular risk factors and biomarkers, multiple regression models were used. In 
these models biomarkers were dependent variables and fasting glucose, waist circumference, 
high-density lipoprotein (HDL), triglycerides (TG), low-density lipoprotein (LDL), systolic 
blood pressure, diastolic blood pressure, smoking, age, sex and creatinine level independent 
variables. 
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3.5 ETHICS APPROVAL 
The studies in the present thesis have ethics approval and were conducted in accordance with 
the Declaration of Helsinki. Ethics approval was obtained separately for cases from the 
Stockholm Regional Ethics Committee (dnr 2004/4:6, 2006/249-32) and controls from the 
Ethics Committee of the Karolinska University Hospital (dnr 91-164, 95:298). All 
participants gave informed consent. 
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4 SUMMARY OF RESULTS 
4.1 PAPER I 
Mean waist circumference in patients compared to controls was for males 106 and 94 cm, 
respectively, and for females 97 and 85cm, respectively (P < 0.001). Mean fasting plasma 
glucose in patients compared to controls was for males 5.8 and 5.2 mmol/L, respectively, and 
for females 5.6 and 4.8 mmol/L, respectively (P < 0.001). Since there were significant 
differences in age and family history of diabetes in cases and control subjects, and these 
variables affect the outcome of interest, these variables were controlled for in the comparative 
analyses. Fifty-three percent of the patients were current smokers and/or snuff users 
compared to 25 percent of the control subjects (χ = 2 240.02, P < 0.001). Fifty percent of 
patients fulfilled the criteria for metabolic syndrome as defined by the International Diabetes 
Federation.  
Risk factors for increased waist circumference and increased fasting glucose were assessed in 
two logistic regression models. Group (control vs. patient), gender, age, tobacco use, family, 
history of diabetes, fasting glucose, fasting insulin and blood pressure were entered as 
independent variables with waist circumference as dependent variable. In the second model 
with fasting glucose as dependent variable the same variables were entered as independent 
variables with the addition of waist circumference. The first regression model showed that all 
variables entered were significantly associated to increased waist circumference. Controlling 
for other risk factors entered in the model, increased waist circumference was almost four 
times (95% CI 3.09 – 5.15) as common among patients with psychosis compared to controls. 
There was no excess risk for increased waist circumference comparing patients with 
schizophrenia and schizoaffective disorder to patients with other diagnoses. In the second 
regression model all variables entered showed significant associations to increased fasting 
glucose. Increased fasting insulin was associated with the highest risk for increased fasting 
glucose (OR = 3.19; 95% CI 2.74 – 3.73). Psychosis was also associated with an increased 
risk for higher fasting glucose (OR = 2.41; 95% CI 1.84 – 3.14). For the variable gender, the 
relation to increased fasting glucose was reversed compared to the risk of increased waist 
circumference, with higher risk for men (OR = 0.45; 95% CI 0.38 – 0.52). Results from the 
two regression analyses are shown in Table 3 and 4. 
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Table 3. Odds ratios (OR) after a logistic regression analysis (stepwise forward) for eight 
independent variables related to increased waist circumference. 
    95% CI  
Independent variable* b SE  (OR)† Lower Upper 
Group 1.38 0.130 3.99 3.09 5.15 
Fasting insulin 1.34 0.070 3.81 3.32 4.37 
Gender 1.11 0.069 3.04 2.65 3.48 
Blood pressure 0.82 0.073 2.27 1.97 2.62 
Fasting glucose 0.68 0.083 1.97 1.68 2.32 
FHDf 0.19 0.063 1.21 1.07 1.37 
Age -0.18 0.065 0.84 0.74 0.95 
Tobacco use 0.17 0.071 1.19 1.03 1.36 
Constant -4.94 0.203    
CI = Confidence Interval 
*Group (control vs. patient); gender (male vs. female); age (≤ 55 vs.>55 yrs); tobacco use 
(smoking or snuffing – no vs. yes); first-degree relative with diabetes (FHD –  no vs. yes); 
fasting glucose (≥5.6 mmol/L –  no vs. yes); fasting insulin (<114 pmol/L vs. ≥114 pmol/L); 
and blood pressure (systolic ≥130 mmHg or diastolic ≥85; and mmHg or antihypertensive 
treatment – no vs. yes) were related to waist circumference (dichotomized: <94 vs. ≥94 cm 
for men, <80 vs. ≥80 for women). All values for these variables are presented with the higher 
value as the second, e.g. male gender = 1 and female= 2, and “No”= 0 and “Yes”= 1. 
†The ORs are arranged in descending order. The OR below 1.00 is inverted before sorting. 
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Table 4. Odds ratios (OR) after a logistic regression analysis (stepwise forward) for eight 
independent variables related to increased fasting glucose. 
    95% CI 
Independent variable* b SE OR† Lower Upper 
Fasting insulin 1.16 0.079 3.19 2.74 3.73 
Group 0.88 0.136 2.41 1.84 3.14 
Gender -0.80 0.079 0.45 0.38 0.52 
Waist circumference 0.71 0.083 2.03 1.73 2.39 
Blood pressure 0.54 0.095 1.72 1.43 2.07 
Age 0.43 0.082 1.54 1.31 1.81 
FHDf 0.38 0.077 1.46 1.26 1.70 
Tobacco use 0.29 0.083 1.34 1.14 1.57 
Constant -4,41 0,233    
CI = Confidence Interval 
*Group (control vs. patient); gender (male vs. female); age (≤55 vs. >55 yrs); tobacco use (smoking or 
snuffing – no vs. yes); first-degree relative with diabetes (FHD –  no vs. yes); fasting insulin (<114 
pmol/L vs. ≥114 pmol/L); blood pressure (systolic ≥130 mmHg or diastolic ≥85; and mmHg or 
antihypertensive treatment – no vs. yes); and waist circumference (dichotomized: <94 vs. ≥94 cm for 
men, <80 vs. ≥80 for women) were related to fasting glucose (≥5.6 mmol/L –  no vs. yes). All values 
for these variables are presented with the higher value as the second, e.g. male gender = 1 and female= 
2, and “No”= 0 and “Yes”= 1. 
†The ORs are arranged in descending order. ORs below 1.00 are first inverted. 
 
4.2 PAPER II 
There was a wide variation in plasma concentration of clozapine in the sample (mean = 1,615 
nM, SD= 1,354 nM). Of 98 patients, 36 (37%) had plasma concentrations of clozapine within 
suggested therapeutic range (1,100-2,100 nM). Patients on a specific dose such as 300 mg/d 
had plasma concentrations within, as well as above and below the suggested range. 
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Figure 1. Relation between clozapine plasma level and daily dose. Measured clozapine 
concentrations at 12 hours after most recent dose plotted against daily dose in 92 patients* 
who had continuous treatment. 
  
*Daily doses of clozapine were available for 92 patients. Two outliers, 7,136 and 8,070 nM, 
are not plotted in the graph. 
 
Smoking was associated with lower plasma concentrations of clozapine (P ≤ .03). We found 
no association between the clinical variables age, gender or weight and plasma concentration 
of clozapine. 
The AA genotype in rs762551 (CYP1A2*F) was significantly associated to lower plasma 
concentrations of clozapine (β = -2.0; 95% CI -3.54 - 0.55). There was also a significant 
association in rs2032582 (MDR1), with GG genotype affecting plasma concentration of 
clozapine in the same direction (β = -1.7, 95% CI -.3.45 - -0.05). The variance of clozapine 
concentration could only to a limited extent be explained by the two genetic variants and 
smoking status (R2 linear = 0.162). 
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Table 5. Relation between independent variables and dose-corrected plasma clozapine 
concentration* 
R² linear = 0.16    
95% Confidence 
Interval  
Independent Variable† β 
Standard 
Error P ≤ Lower Upper 
CYP1A2 rs762551 AA genotype -2.0 0.75 .008 -3.54 -0.55 
Currently smoking -1.8 0.76 .03 -3.31 -0.28 
MDR1 rs2032582 GG genotype -1.7 0.85 .05 -3.45 -0.05 
Constant 11.4 1.69 .001 8.02 14.72 
*Multiple regression analysis (stepwise forward). 
†rs762551 AA genotype (ref = no); smoking status (ref = no); rs2032582 GG genotype (ref = no) 
 
We found no relation between plasma concentrations of clozapine and increased waist 
circumference or fasting glucose. However, the AA genotype in rs762551 (CYP1A2*F), 
associated to lower plasma concentrations of clozapine was also associated to a lower risk of 
increased fasting glucose (OR = 0.27; 95% CI 0.10 - 0.72). Increased fasting glucose was 
also more common in males (OR = 5.28; 95% CI 1.88 – 14.89) and in older patients (OR = 
1.08; 95% CI 1.03 -1.13). There were no significant effects of the different genotypes, 
gender, age or smoking status on the risk of increased waist circumference.  
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Table 6. Relation between independent variables related to raised fasting plasma glucose 
(>5.6 mmol/L or antidiabetic treatment)* 
    
95% Confidence 
Interval 
Independent Variable† 
Odds 
Ratio 
Standard 
Error P ≤ Lower Upper 
Sex  5.28 2.79 .002 1.88 14.89 
rs762551 AA genotype 0.27 0.13 .009 0.10 0.72 
Age (y) 1.08 0.03 .001 1.03 1.13 
*Logistic regression analysis (stepwise forward). 
†Sex (women = 0; men = 1); rs762551 AA genotype (no = 0; yes = 1). 
 
4.3 PAPER III 
Patients without antidiabetic pharmacotherapy had significantly higher fasting glucose as 
compared to control subjects, controlling for differences in age and gender (P = .001). There 
were significant differences in frequencies of diabetes and prediabetes (fasting glucose level 
6.1 – 6.9 mM) between cases and control subjects, also controlling for differences in age and 
gender (P = .001; P = .001). Patients with schizophrenia were found to have significantly 
higher mean fasting glucose levels compared to patients with other psychiatric diagnoses. 
Both prediabetes and diabetes were approximately three times more frequent among patients 
with psychosis as compared to controls. The differences between patients with psychosis and 
control subjects in prevalence of prediabetes and fasting glucose 5.6-6.0 mM were most 
pronounced in younger age categories. Of patients with psychosis and prediabetes 77 percent 
also fulfilled the criteria for metabolic syndrome. There were no significant differences in 
antidiabetic pharmacological treatment comparing patients with psychosis and control 
subjects (P = .114). 
The logistic regression analysis, investigating factors potentially associated with antidiabetic 
pharmacological treatment in patients with psychosis diagnosed with diabetes, yielded odds 
ratios as a measure of the association. In this analysis, lipid lowering treatment (OR = 6.74; 
95% CI 1.88 – 24.13) and high fasting glucose (OR = 1.24; 95% CI 1.01 - 0.72) were 
associated with antidiabetic pharmacological treatment. Smoking status, metabolic syndrome, 
waist circumference, Global Assessment of Functioning scale, Clinical Global Impression 
scale, and antihypertensive treatment, duration of antipsychotic medication and number of 
months in hospital during the previous year did not show any association with antidiabetic 
pharmacological treatment. When patients with schizophrenia were analyzed separately a 
negative association, in addition to the two previous associations, was found between 
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duration of antipsychotic treatment and antidiabetic pharmacological treatment (OR = 0.88; 
95 CI 0.79 - 0.97). 
 
Table 7. Antidiabetic treatment, achievement of fasting glucose < 7 mmol/L in patients with 
psychotic disorders and control subjects with diabetes* 
Glucose Levels 
Psychosis 
Patients† Control Subjects P 
DM diagnosis 94 (10.0) ‡ 69 (1.8) .001§ 
 DM diagnosis and antidiabetic treatment 40 (42.6) 38 (55.1) .114 
 Metabolic syndrome 33 (82.5) ND - 
 Fasting glucose < 7.0 mmol/L 13 (32.5) 12 (31.6) .931 
 DM diagnosis and no antidiabetic treatment 54 (57.4) 31 (44.9) .114 
 Metabolic syndrome 41 (77.4) ND - 
 Fasting glucose < 7.0 mmol/L 32 (59.3) 18 (58.1) .914 
*Data reported as number (%). Among controls only subjects who developed diabetes during the 
follow up period are included. 
Abbreviations: DM, diabetes mellitus; ND, not determined. 
†No. of patients varied due to sporadic missing information. 
‡2 psychosis patients with insulin treatment without DM diagnosis were included. 
§P from logistic regression models controlling for differences in sex and age. 
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Table 8. Increased fasting glucose in patients and control subjects without diabetes* 
Glucose Levels 
Psychosis 
Patients† 
Control 
Subjects P 
No DM diagnosis 854 (90.1) 3839 (98.2) .001‡ 
 Fasting glucose ≥ 7.0 mmol/L 43 (5.0) 41 (1.1) .001‡ 
 Metabolic syndrome 32 (76.2) ND - 
 Fasting glucose 6.1-6.9 mmol/L 87 (10.2) 149 (3.8) .001‡ 
 Metabolic syndrome 64 (77.1) ND - 
 Fasting glucose 5.6-6.0 mmol/L 160 (18.7) 355 (9.1) .001‡ 
 Metabolic syndrome 103 (65.2) ND - 
*Data reported as number (%). 
Abbreviations: DM, diabetes mellitus; ND, not determined. 
†No. of patients varied due to sporadic missing information. 
‡P from logistic regression models controlling for differences in sex and age. 
 
4.4 PAPER IV 
Levels of biomarkers, in previous studies associated with elevated cardiovascular risk, were 
elevated above reference values in the current sample of patients with psychosis in regular 
treatment. A large proportion of patients, 29 percent (95% CI 23.9 - 34.1), had hsCRP levels 
of 3 – 10 mg/L, eight percent (95% CI 4.7-10.7) had pathological hsTnT levels and seven 
percent (95% CI 4.4-10.3) had pathological NT-BNP levels. Of patients with of hsTnT ≥ 15 
ng/L, 44 percent had a diabetes diagnosis, 47 percent a diagnosis of hyperlipidemia, 28 
percent a history of chest pain and only eleven percent were present smokers.  
In the univariate analyses hsTnT and hsCRP were significantly correlated to more clinical 
cardiovascular risk factors than NT-BNP. HsTnT showed significant positive correlations to 
fasting glucose level, waist circumference, systolic blood pressure, diabetes diagnosis and 
diagnosis of hyperlipidemia. HsCRP had significant positive correlations to body mass index, 
triglyceride level, fasting glucose level, systolic and diastolic blood pressure HsCRP also 
showed a significant negative correlation to European quality of life-5 dimensions index (EQ-
5D). NT-BNP had a significant positive correlation to previous diagnosis of acute myocardial 
infarction (AMI), and was negatively correlated to EQ-5D. The biomarkers were poorly 
correlated to each other with only a small but significant positive correlation between NT-
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BNP and hsTnT. The regression model with hsTnT as the dependent variable and clinical 
cardiovascular risk factors as independent variables explained 37.9 percent of the variance of 
hsTnT (R2 linear = 0.379). In this model, waist circumference was significantly associated 
with increased levels of hsTnT (standardized coefficient = 0.20; SE 0.02), controlling for 
differences in age, sex, plasma creatinine and fasting glucose level. Fasting glucose was also 
associated to increased levels of hsTnT (standardized coefficient = 0.21; SE 0.18), controlling 
for the same factors with the addition of waist circumference. Gender, age and plasma 
creatinine were also significantly associated with levels of hsTnT. None of the other 
independent cardiovascular risk factors entered in the model showed any significant 
association (Table 10). 
  
  31 
Table 9. Clinical and demographic characteristics, hsTnT, NT-BNP and hsCRP in patients 
with psychosis 
 Patients with psychosis 
 
Men 
(n = 147) 
Women 
(n = 153) 
Age (years) 54 ± 7 58 ± 9** 
Present smoker† 38 (45) 35 (43) 
BMI (kg/m2) 28 ± 5 29 ± 6 
Waist (cm) 105 ± 14 99 ± 14* 
Systolic blood pressure (mm Hg) 132 ± 18 131 ± 18 
Diastolic blood pressure (mm Hg)  83 ± 11 84 ± 11  
Fasting glucose (mmol/L) 6.0 ± 2.1 5.6 ± 1.1 
Total Cholesterol (mmol/L) 5.3 ± 1.4 5.7 ± 1.1 
LDL Cholesterol (mmol/L) 3.4 ± 0.9 3.6 ± 1.1 
HDL Cholesterol (mmol/L) 1.1 ± 0.3 1.4 ± 0.4***  
Triglycerides (mmol/L) 1.8 ± 1.6 1.4 ± 0.7*  
Biomarkers   
HsTnT (ng/L) 7 ± 6  4 ± 5***  
HsTnT ≥ 15 ng/L 10 (15) 5 (8) 
NT-BNP (ng/L) 86 ± 442 95 ± 122*** 
NT-BNP > 100 ng/L 11 (16) 27 (42)*** 
NT-BNP > 150 ng/L 4 (6) 14 (22)* 
HsCRP (mg/L) 3.2 ± 3.7  3.6 ± 5.2  
HsCRP < 1 35 (51) 29 (45) 
HsCRP 1-3  33 (49) 31 (48) 
HsCRP > 3 32 (47) 39 (60) 
HsCRP 3-10 26 (38) 32 (49) 
HsCRP > 10 6 (9) 7 (11) 
Data reported as mean ± standard deviation or % (number). 
*p < 0.01, **p<0.001, ***p<0.0001 
†No. of patients varied due to sporadic missing information. 
Abbreviations: BMI, body mass index; LDL, low density lipoprotein; HDL, high density 
lipoprotein; BNP, N-Terminal Pro-B-Type Natriuretic Peptide; CRP, high-sensitive C-
reactive protein 
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Table 10. Relation between independent variables and hs-TnT in a multiple regression 
analysis (stepwise forward). 
 
 Unstandardized 
coefficients 
 Standardized coefficients  
Independent Variable B SE t Beta  
Age 0.31 0.04 7.78 0.43  
Gender (1= man; 2= woman) -2.35 0.74 -3.19 -0.20  
Waist circumference 0.08 0.02 3.58 0.20  
Plasma creatinine 0.07 0.02 3.20 0.19  
Fasting glucose 0.71 0.18 3.91 0.21  
Constant -25.90 3.75 -6.91 -  
R2 linear 0.379       
Abbreviations: SE= Standard Error 
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5 DISCUSSION 
5.1 STUDY I 
In our opinion, the most important finding was the substantially increased risk in patients 
with psychosis of having increased waist circumference and increased fasting glucose 
compared to control subjects. The elevated risk of increased waist circumference was 
significant, controlling for differences in fasting insulin, sex, blood pressure, fasting glucose, 
family history of diabetes, age and tobacco use. The increased risk of higher fasting glucose 
was observed controlling for the same factors with addition of waist circumference. This 
implies that the mechanism by which antipsychotic drugs can raise fasting glucose levels and 
cause glucose disturbances and diabetes is not only through weight gain and increased insulin 
resistance. Increased hepatic glucose output (HGO) and direct effects on insulin and glucagon 
secretion from pancreatic islets have been suggested as other important mechanisms (Smith et 
al., 2014). 
Smoking was significantly more common among patients with psychosis compared to 
controls. A selection bias with “super healthy” control subjects might be present and 
overestimate differences. In contrast, the cases are outpatients, and compared to an inpatient 
sample, they are likely to have lower smoking prevalence. This is supported by the fact that 
the prevalence of smoking in the current material was lower than the prevalence reported in a 
large retrospective cohort of patients with severe mental illness (44 vs 61%) (Osborn et al., 
2006). Furthermore, the sample in the current study included all patients in regular psychosis 
outpatient treatment. Smoking prevalence is likely to be lower in such a sample compared to 
smoking prevalence in a sample consisting of schizophrenia patients only. In conclusion, 
smoking still seems to be considerably more prevalent in patients with psychosis compared to 
controls, possibly contributing to the excess cardiovascular mortality and morbidity. 
 
5.2 STUDY II 
There was a wide variation in plasma concentration of clozapine with 37 percent of patients 
within the suggested therapeutic range (1,100 – 2,100 nM). Patients on a specific dose of 
clozapine such as 300 mg/d had plasma concentrations within, above and below therapeutic 
range. Individual clinical and genetic factors could only to a limited extent explain the 
variance in concentrations of clozapine. The factors that seemed to affect clozapine 
concentration were smoking habits, variants of CYP1A2 and variants of MDR1. In line with 
results from study I, increased fasting glucose was associated with plasma concentrations of 
clozapine, independent of increased waist circumference. The results also indirectly suggest 
that risk of increased fasting glucose is concentration dependent. One possible explanation for 
the absence of association between metabolism affecting factors, plasma concentration of 
clozapine and waist circumference might be that it is weight increase and the subsequent 
increase in waist circumference that is associated to plasma concentration and not current 
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waist circumference. Furthermore, the results confirm that CYP1A2 is central in the 
metabolism of clozapine.  
 
5.3 STUDY III 
The main finding of the study was the high frequency of prediabetes (FPG 6.1 – 6.9 mM) in 
patients with psychosis compared to controls (10.2 vs 3.8%). In patients with psychosis and 
prediabetes, 77 percent also fulfilled the criteria for metabolic syndrome. Patients with 
metabolic syndrome have a high risk of developing manifest diabetes. There are established 
life-style interventions and pharmacotherapies to prevent or delay the onset of diabetes 
(Diabetes Prevention Program Research et al., 2009; Merlotti, Morabito, & Pontiroli, 2014). 
The present study proposes that reduced progression from prediabetes to diabetes should be a 
treatment goal for patients with psychosis. Considering previous progression rates for obese 
subjects of 10-12 percent (Knowler et al., 2002; Tuomilehto et al., 2001) to be valid also in 
patients with psychosis, approximately eight to ten patients out of 854 progress to manifest 
diabetes yearly. Regular use of Metformin would be expected to lower the progression rate 
substantially and has previously been reported to lower it by as much as 30% (Knowler et al., 
2002). Patients with psychosis and no diagnosis of diabetes had higher fasting plasma glucose 
levels compared to controls. Furthermore, more patients with psychosis and no diabetes 
diagnosis had FPG ≥ 7.0 mM compared to controls. This could be explained by patients 
having a longer time to diabetes diagnosis compared to controls. However, this conclusion 
could be afflicted by bias since controls with diabetes at baseline were excluded. 
 
5.4 STUDY IV 
The three biomarkers, NT-BNP, hsTnT and hsCRP were elevated in blood samples from 
psychosis patients without pre-existing cardiovascular disease during regular anti-psychotic 
treatment. A large proportion 29 percent (95% CI 23.9 - 34.1) had hsCRP levels of 3 – 10 
mg/L. Eight percent (95% CI 4.8-10.6) had pathological hsTnT and seven percent (95% CI 
4.4-10.3) pathological NT-BNP levels. Furthermore, one percent had pathological values in 
all three biomarkers. With increased levels of biomarkers, it was most common that a single 
biomarker was clearly dominating, i.e. was above reference value. Together with the fact that 
NT-BNP, hsTnT and hsCRP reflect wall stress, myocardial cell damage and inflammation 
respectively this could imply that each biomarker contribute with unique information. This is 
also supported by NT-BNP, hsTnT and hsCRP being poorly correlated to each other. 
HsCRP showed significant positive correlations to different measures of overweight in the 
univariate analyses, in line with previous findings suggesting an association between 
inflammation and metabolic disturbances in these patients (Miller, Mellor, & Buckley, 2013). 
Other processes engaging the immune system such as chronic obstructive lung disease and 
the psychotic disease itself can possibly also contribute to the elevated levels of hsCRP in 
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these patients. The majority of patients with chronic inflammatory conditions are however 
excluded when patients with CRP levels of less than 10 mg/L are studied. Patients with CRP 
levels of 3 – 10 mg/L are also the group of patients previously associated to the highest risk 
of overweight (Wium-Andersen, Orsted, Nielsen, & Nordestgaard, 2013). 
Clinical cardiovascular risk factors were more closely associated to hsTnT as compared to 
hsCRP and NT-BNP. HsTnT, in contrast to NT-BNP and hsCRP, was significantly 
associated with larger waist circumference and higher fasting glucose level in a regression 
analysis with established clinical risk factors as independent variables. Unfortunately, the 
study was not able to study potential advantage of biomarkers of increased cardiovascular 
risk over traditional clinical risk factors e.g. diabetes, tobacco use, blood pressure, body mass 
index, and waist circumference. It is important to point out that the best biomarker of 
increased cardiovascular risk is not the biomarker most closely associated to clinical already 
established risk factors but a biomarker which identifies high-risk individuals not identified 
by traditional risk factors. If biomarkers do add information for better stratification of 
cardiovascular risk, they should be used as guidance for counteraction and reduction of 
cardiovascular risk among patients with psychosis. 
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6 CONCLUSIONS 
There is a demand for biomarkers for somatic health monitoring and as guidance for 
prevention of cardiovascular events in patients with psychotic disorder. Psychiatrists should 
collaborate closely with general practitioners and cardiologists. Basic pharmacological 
treatment of medical conditions, monitoring of risk factors and organizational structures of 
somatic referral should be handled by the psychiatrist. 
Psychosis is associated to higher fasting glucose levels and increased waist circumference 
compared to controls. Furthermore, the frequency of smoking is clearly higher among 
patients with psychosis compared to controls. Also, we conclude that the mechanisms by 
which antipsychotic agents cause glycemic disturbances are complex and as yet far from fully 
understood. 
Regular therapeutic drug monitoring is advised for patients on antipsychotic treatment with 
clozapine. The main reasons for this are the following: (1) it is difficult to predict plasma 
concentration of clozapine even when clinical and genetic factors are considered; (2) only 37 
percent of patients studied had plasma concentrations within suggested therapeutic interval; 
(3) on a specified dose patients had plasma concentrations within, above and below suggested 
therapeutic interval; (4) there were patients with exceptionally high concentrations. CYP1A2 
is important in the metabolism of clozapine and functional gene variants are common. Of the 
clinical factors investigated, smoking had the largest effect on plasma concentrations of 
clozapine. For clozapine, a strong case could also be made in favor of systematic prospective 
treatment studies to improve the assessment of recommended drug levels. In addition, a 
strong case could also be made for monitoring other antipsychotic drugs, which may increase 
treatment effects and reduce drug adverse effects. 
Approximately one out of ten patients with psychosis had prediabetes (FPG 6.1 – 6.9 mM). 
Prediabetes is more common in patients with psychosis compared to population controls. A 
majority of patients with psychosis and prediabetes also fulfill the criteria for metabolic 
syndrome. This suggests that the progression rate from prediabetes to manifest diabetes is 
higher among patients with psychosis compared to the population. Treatment of prediabetes 
in patients with psychosis with life-style interventions and/or pharmacotherapy is proposed in 
this thesis, and reduced progression to diabetes as an important treatment goal. Biomarkers 
associated with cardiovascular risk in previous studies were elevated in patients with 
psychosis. Since endpoint data of cardiovascular events were not available, it was not 
possible to assess if biomarkers add information to risk stratification.  
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7 IMPLICATIONS FOR FUTURE RESEARCH 
Future studies should focus on assessing modifiable cardiovascular risk factors among 
patients with psychosis, and testing the effect sizes in prospective randomized clinical 
efficacy studies. Reduced progression of prediabetes to diabetes, weight reduction and 
smoking cessation should be given extra attention. Concerning prediabetes, prospective 
studies should evaluate the potential preventive effect on diabetes of life-style programmes 
and pharmacological interventions with metformin and possibly newer agents. 
Future studies of clozapine should focus on collecting data enabling us to understand why 
patients on clozapine discontinue treatment. Broadening our understanding of the effect of 
clozapine is a critical part to the solution of this dilemma. We are planning a clozapine 
project to shed some light on these issues. In this project we aim to collect data on effect of 
treatment and enroll patients currently on clozapine treatment and patients who have recently 
discontinued treatment. A special unit within the organization specifically for patients on 
clozapine treatment, in conformity with patients on lithium treatment, is going to be the 
structure of the project. One interesting part of the project involves induced pluripotent stem 
cells (IPS). With this technique it is possible to grow the patient’s own dopamine cells from 
fibroblasts attained with a skin biopsy. Since the antipsychotic effect of neuroleptic drugs is 
thought to be mediated by the dopamine system, specifically by blocking the dopamine D2 
receptor, it is possible that the systems differ between responders and non-responders. With 
this technique we should be able to study dopamine cells and the dopamine D2 receptors 
expressed on dopamine cells. Clozapine is well known to have direct and indirect effects also 
on other receptors, including the serotonin receptor and the glutamate receptor. The complex 
effects of clozapine on different signaling systems is thought to be the explanation for the 
unique effect of the compound. From neuronal stem cells it is possible to cultivate cells 
expressing different receptors, including the glutamate receptor. In this project we also intend 
to study genes, gene expression, plasma levels of clozapine and cerebrospinal fluid.  
Prospective studies should evaluate the potential advantage of biomarkers of cardiovascular 
risk in patients with psychosis in regular treatment. A confirmed advantage of biomarkers 
should lead to them being added to clinical guidelines for management of patients with severe 
mental illness. As a next step, our research team plans a follow-up study with the cohort from 
study IV as baseline. 
A general implication of the findings of this thesis is that there is likely to be substantial 
clinical improvement for psychosis patients by further clinical studies along the directions of 
the studies included. 
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